Skip to Content

Bioasis Technologies Inc BIOAF

Morningstar Rating
$0.01 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BIOAF is trading at a 38% discount.
Price
$0.00
Fair Value
$1.74
Uncertainty
Extreme
1-Star Price
$5.52
5-Star Price
$3.13
Economic Moat
Rwcmn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BIOAF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.000.02
Bid/Ask
$0.01 / $0.01
Market Cap
$397,070.08
Volume/Avg
8,025 / 37,897

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees

Valuation

Metric
BIOAF
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
BIOAF

Financial Strength

Metric
BIOAF
Quick Ratio
0.05
Current Ratio
0.11
Interest Coverage
−2.04
Quick Ratio
BIOAF

Profitability

Metric
BIOAF
Return on Assets (Normalized)
−178.00%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
BIOAF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFwcw$550.2 Bil
VRTX
Vertex Pharmaceuticals IncRxmfh$111.1 Bil
REGN
Regeneron Pharmaceuticals IncLlmdmbj$107.7 Bil
MRNA
Moderna IncBrcl$36.9 Bil
ARGX
argenx SE ADRNcmb$24.2 Bil
BNTX
BioNTech SE ADRXcpm$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncYxtmgs$19.9 Bil
BMRN
Biomarin Pharmaceutical IncWrdgdxj$17.2 Bil
RPRX
Royalty Pharma PLC Class ABkxwhn$13.9 Bil
INCY
Incyte CorpFnswvvj$13.6 Bil

Sponsor Center